questionText: To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the (a) voluntary scheme for branded medicines pricing, access and growth and (b) statutory scheme payment rates on attracting pharmaceu
answerText: Life sciences is a key growth-driving sector and is a core part of our modern Industrial Strategy. The 2024 Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) introduced, for the first time, an approximately £400 million industry-funded VPAG...
heading: Drugs: Prices